

# Table of Contents

<b>1. Introduction.....</b>	<b>1</b>
1.1. Mission .....	3
1.2. Ethical Principles.....	3
1.2.1. IRB Independence from Undue Influence.....	4
1.2.2. Institutional Conflict of Interest .....	4
1.2.3. Conflicts of Interest Policies for Faculty, Senior Officers and Others .....	4
1.3. Applicable Laws.....	4
<b>2. Roles and Responsibilities .....</b>	<b>5</b>
2.1. Responsibilities of the Institution.....	5
2.1.1. Resources for the CHS .....	5
2.2. Responsibilities of the Institutional Official.....	6
2.3. Responsibilities of the CHS.....	7
2.4. Responsibilities of the CHS Office .....	8
2.5. Responsibilities of the Investigator .....	8
2.6. Responsibilities of Unaffiliated Investigators and Unaffiliated Institutions .....	9
2.7. Additional Institutional Support and Responsibility .....	10
2.8. Quality Assurance .....	12
2.8.1. Monitoring of the CHS.....	12
2.8.1.1. Quality Assurance Coordinator.....	12
2.8.1.2. CHS Leadership Team.....	13
2.8.1.3. Institutional Official.....	14
2.8.1.4. University Level.....	14
2.8.1.5. Federal Level .....	14
2.8.2. Researcher Grievances, Comments, or Suggestions .....	14
<b>3. CHS Member and Staff Policies .....</b>	<b>14</b>
3.1. CHS Chair .....	14
3.1.1. CHS Chair Qualifications.....	15
3.1.2. CHS Chair Training .....	15
3.1.3. Expectations for the CHS Chair .....	15
3.2. CHS Members .....	15
3.2.1. CHS Composition .....	16
3.2.2. CHS Member Training.....	16
3.2.3. Expectations for CHS Members.....	17
3.3. CHS Consultants .....	17
3.3.1. CHS Consultant Qualifications .....	18
3.3.2. CHS Consultant Training .....	18
3.3.3. Expectations for CHS Consultants .....	18
3.4. CHS Member Conflict of Interest .....	18
3.4.1. Professional/Personal Conflict of Interest.....	19
3.4.2. Financial Conflict of Interest.....	19
3.5. CHS Member Indemnification .....	19
3.6. CHS Primary Reviewer System .....	20
3.7. CHS Meeting Schedule .....	21
3.8. CHS Quorum.....	21
3.9. CHS Staff .....	21

<b>4.</b>	<b>Initial Review of Research.....</b>	<b>22</b>
4.1.	Office Procedures for Processing New Applications .....	22
4.2.	Definitions .....	23
4.3.	Proposals Not Meeting the Definition of Research Involving Human Subjects in Section 4.2 ...	25
4.4.	Scientific Review.....	26
4.4.1.	Additional Consultant for Scientific Review .....	26
4.5.	Ethical Review .....	27
4.6.	Funding Review .....	27
4.7.	Investigator/Research Staff Experience.....	27
4.7.1.	Investigator Conflict of Interest .....	28
4.8.	Research Meeting Exempt Review Categories .....	29
4.8.1.	Review of Research Proposals for Exemption Criteria.....	30
4.8.2.	Unacceptability of Investigator Self-Exemptions .....	31
4.8.3.	Exemption Criteria .....	31
4.8.4.	Applicability of Exemption Criteria to Vulnerable Populations (45 CFR § 46 Subparts B, C and D) 33	
4.9.	Research Meeting Expedited Review Categories.....	33
4.9.1.	Review of Research Proposals for Expedited Criteria .....	34
4.9.2.	Categories of Research that may be Reviewed through an Expedited Review Procedure....	34
4.9.2.1.	Applicability .....	34
4.9.2.2.	Research Categories.....	35
4.9.3.	Reviewer Determination .....	36
4.9.4.	When there are Contingencies for Approval.....	37
4.9.5.	Notification to Investigators.....	37
4.9.6.	CHS Approvals and Release of Funds for Research.....	37
4.10.	Research Requiring Full Committee Review .....	38
4.10.1.	Research Involving More than Minimal Risk .....	38
4.10.2.	Proposals Not Involving More than Minimal Risk, but that Require Full Committee Review 38	
4.10.3.	Document Distribution.....	38
4.10.4.	CHS Review Procedures .....	39
4.10.5.	CHS Determinations .....	39
4.10.5.1.	Voting Validity .....	39
4.10.5.2.	Participation by Telephone .....	39
4.10.5.3.	CHS Actions and Notifications.....	40
4.11.	Research Requiring Review More Often than Annually .....	41
4.12.	Research Monitoring .....	42
4.13.	International or Off-Site Research and Knowledge of the Local Research Context.....	42
<b>5.</b>	<b>Continuing Review of Research.....</b>	<b>42</b>
5.1.	Required Continuation Submission Documentation .....	43
5.2.	CHS Office Processing of Continuing Review Submissions .....	43
5.3.	Continuing Review by the Full Committee.....	44
5.4.	Continuing Review of Research Meeting Expedited Categories .....	45
5.5.	Lapse in Continuing Review Approval .....	45
5.5.1.	Investigator Reports for Lapsed Studies .....	45
5.5.2.	Review of Lapsed Approval of an Expedited Study .....	46
5.5.3.	Review of Lapsed Approval for a Study Requiring Full-CHS Review .....	46
5.5.4.	File Closure of Lapsed Studies.....	46
5.5.5.	Reporting Study Lapses to OHRP and other Regulatory Agencies .....	46
5.5.6.	CHS Administrative Functions Resulting in Study Lapses.....	46

5.6.	CHS Study and File Closure.....	47
<b>6.</b>	<b>Amendments to Research Activity .....</b>	<b>47</b>
6.1.	Amendment Requests.....	47
6.2.	Required Materials for Amendment Requests.....	47
6.3.	CHS Procedures for Processing Amendment Requests .....	48
6.4.	Document Distribution to CHS Members .....	48
6.5.	Amendment Review by the Convened CHS .....	48
6.6.	Amendment Review Meeting Expedited Categories.....	49
6.7.	Modifications to Research Resulting from Emergency Procedure/Process .....	49
6.8.	Amendment Review of Studies Meeting Exemption Criteria .....	49
<b>7.</b>	<b>Ceding Review.....</b>	<b>50</b>
7.1.	Definitions.....	50
7.1.1.	Cooperative Agreements and Reliance Agreements .....	50
7.1.2.	IRB Authorization Agreements (IAA).....	50
7.2.	Conditions for Ceded Review .....	51
7.2.1.	Accepting Review Responsibilities for another Institution.....	51
7.2.2.	Ceding Review to other Institutions.....	51
7.2.3.	Harvard Clinical and Translational Science Center (CTSC).....	52
7.3.	Required Documentation for Ceded Review.....	52
7.4.	Procedures for Ceded Review .....	52
7.4.1.	Initial Approval .....	52
7.4.2.	Continuing Approval.....	53
7.4.3.	Amendments, Non-Compliance, and Unanticipated Problem Reporting .....	53
7.4.4.	File Closure .....	54
<b>8.</b>	<b>Multi-Site Studies.....</b>	<b>54</b>
8.1.	Where the Faculty of Medicine is the recipient of the primary funding award (regardless of the source), and the research is conducted at HMS or HSDM (with additional sites coordinated by the HMS/HSDM Investigator) .....	54
8.2.	Where the Faculty of Medicine is the recipient of a primary funding award and the Principal Investigator is an HMS/HSDM faculty member who is based at a Harvard-affiliated institution where the research will be taking place .....	55
8.3.	Where the Faculty of Medicine is the recipient of a subcontract funding award and the research is taking place at HMS or HSDM .....	55
8.4.	Where an HMS/HSDM Investigator who is based at a Harvard-affiliated institution is the recipient of a subcontract funding award from the Faculty of Medicine and the research is taking place at the Harvard-affiliated institution .....	56
8.5.	Where there is no external funding to the Faculty of Medicine and the HMS/HSDM Investigator is the Principal Investigator and additional sites are coordinated by the Investigator.....	56
8.6.	Where an HMS/HSDM Investigator who is based at a Harvard-affiliated institution receives no external funding through the Faculty of Medicine and the research is taking place at the Harvard-affiliated institution .....	56
8.7.	Where the primary research funds are awarded to the Faculty of Medicine and may or may not include a subcontract to the Institution where the research is taking place and where the HMS/HSDM Investigator has no affiliation.....	56
8.8.	Where the subcontract research funds are awarded to Faculty of Medicine and the research is taking place at an Institution where the Investigator has no affiliation.....	56
<b>9.</b>	<b>Research by Faculty of Medicine Students.....</b>	<b>57</b>
9.1.	Mentors.....	57

9.1.1.	Mentor Letters/Letters of Support.....	57
9.1.1.1.	HMS and HSDM Faculty Letters .....	57
9.1.1.2.	On-Site Mentor Letters/Letters of Support .....	57
9.1.2.	HSDM Faculty Advisors.....	58
9.2.	Funding for Student Research .....	58
9.2.1.	Faculty of Medicine Office of Enrichment Programs (OEP).....	58
9.2.2.	Fellowship Monies .....	58
9.2.3.	Extramural Funding .....	58
9.3.	CHS Student Submission Requirements .....	59
9.4.	Communication .....	59
9.5.	Institutional Approvals .....	59
9.5.1.	CHS Approval.....	60
9.5.2.	Research Site Approvals .....	60
9.5.3.	Ceded Review of Student Research .....	60
<b>10.</b>	<b>Policies and Criteria for IRB Approval.....</b>	<b>60</b>
10.1.	Participation Review .....	60
10.1.1.	Equitable Selection of Participants .....	60
10.1.2.	Risks vs. Benefits .....	61
10.1.3.	Data Safety Monitoring.....	62
10.1.3.1.	Data Safety Monitoring Plans (DSMPs).....	62
10.1.4.	Privacy.....	63
10.1.5.	Confidentiality of Data.....	63
10.1.6.	Certificates of Confidentiality .....	63
10.1.7.	Remuneration Guidelines .....	64
10.2.	Recruitment .....	65
10.2.1.	Recruitment Guidelines.....	65
10.2.2.	Recruitment Materials .....	65
10.2.3.	CHS Review of Recruitment Materials.....	66
10.3.	Informed Consent Guidelines.....	66
10.3.1.	Informed Consent Form .....	67
10.3.1.1.	Basic Elements of Informed Consent.....	67
10.3.1.2.	Documentation of Consent .....	69
10.3.2.	Guidelines for Waiver or Alteration of Consent Requirements .....	70
10.3.2.1.	Waiver Requests to the CHS.....	70
10.4.	Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule .....	71
10.5.	CHS Review of HIPAA Waivers of Patient Authorization.....	72
<b>11.</b>	<b>Vulnerable Populations and Special Protections .....</b>	<b>72</b>
11.1.	Pregnant Women, Neonates, and Fetuses.....	73
11.1.1.	Pregnant Women and Fetuses .....	73
11.1.1.1.	Federal Regulations Involving Pregnant Women and Fetuses.....	73
11.1.1.2.	Massachusetts Law Involving Fetuses in Research .....	74
11.1.2.	Neonates .....	75
11.1.3.	Research Involving, After Delivery, the Placenta, the Dead Fetus or Fetal Material .....	76
11.1.4.	Research not otherwise approvable that present an opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of pregnant women, fetuses, or neonates .....	76
11.2.	Prisoners .....	76
11.2.1.	Additional CHS Composition Requirements .....	77
11.2.2.	Additional Issues for Consideration by the CHS .....	77
11.2.3.	DHHS-Funded Research Involving Prisoners.....	78
11.2.4.	Expedited Review Procedures.....	79

11.2.5. Exempt Research with Prisoners.....	79
11.3. Children.....	79
11.3.1. Research Not Involving Greater than Minimal Risk.....	81
11.3.2. Research involving greater than minimal risk but presenting the prospect of direct benefit to the individual child participants.....	81
11.3.3. Research involving greater than minimal risk and no prospect of direct benefit to the individual child participants, but likely to yield generalizable knowledge about the participant’s disorder or condition.....	82
11.3.4. Research not otherwise approvable that presents an opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of children.....	82
11.3.5. Requirements for Permission by Parents or Guardians.....	83
11.3.6. Requirements for Assent by Children.....	83
11.3.7. Additional Requirements for Wards and Foster Children.....	84
11.3.8. Child Abuse Reporting.....	84
11.3.9. Confidential Birth Information.....	85
11.4. Embryonic Stem Cell Research.....	86
11.5. Participants with Cognitive Impairments.....	86
11.5.1. Research outside the jurisdiction of the Massachusetts Department of Mental Health (DMH).....	86
11.5.2. Research within the Jurisdiction of the DMH.....	87
11.5.3. Research Protocol Considerations.....	87
11.5.4. Assent, Consent, and Legally Authorized Representatives and Proxy Consent.....	88
11.5.4.1. Additional Policies Relating to Proxy Consent.....	90
11.6. Participants with Limited Capacity to Speak English.....	90
11.7. Participants with Economic Disadvantages.....	91
11.8. Participants with Educational Disadvantages.....	92
11.9. Participants with Stigmatizing Conditions.....	92
11.10. Participants who are Students, Fellows, or Employees of Harvard University.....	93
11.10.1. Curriculum Studies and Studies Specifically Recruiting Students.....	94
11.10.1.1. Harvard Medical School.....	94
11.10.1.2. Harvard School of Dental Medicine.....	94
11.11. Investigator Self-Experimentation.....	94
<b>12. Clinical Research.....</b>	<b>95</b>
12.1. Studies Involving Drugs in Research.....	96
12.1.1. Massachusetts Requirements.....	96
12.1.2. Use of FDA-Approved Drugs in Research.....	97
12.2. Use of Devices in Research.....	98
12.2.1. Significant/Non-Significant Device Determinations by the CHS.....	99
12.2.2. Exemption from the Requirement for an IDE.....	100
12.2.3. Requirements for Investigators using Drugs or Devices in Research.....	101
12.2.4. Clinical Research Requirements for Sponsored Programs Administrators (including Grant and Contract Officers and CHS Administrators).....	101
<b>13. Adverse Events and Unanticipated Problems.....</b>	<b>102</b>
13.1. When and How to Report Events to the CHS.....	104
13.1.1. When there is a Data Safety Monitoring Board or Committee (DSMB/C).....	104
13.2. CHS Review of Reported Problems.....	104
13.3. Document Distribution.....	105
13.3.1. Notification of CHS Determinations to Investigator, Institutional Officials, and Regulatory Agencies.....	106

<b>14. Non-compliance with 45 CFR § 46, HU or CHS Policies/Procedures.....</b>	<b>107</b>
14.1. Definitions .....	107
14.2. Investigator Reports of Protocol Deviations and Non-Compliance .....	107
14.2.1. What to Report to the CHS .....	107
14.2.2. When to Report to the CHS.....	108
14.2.3. Other Allegations or Reports of Non-Compliance.....	108
14.2.4. Initial Inquiry .....	108
14.3. Further Investigation by the CHS .....	110
14.4. Confidentiality .....	110
14.5. Coordination with Other Investigative Process .....	110
14.6. Action Prior to Decision.....	111
14.7. Decision (including suspension or termination of approval).....	111
14.8. Notification of CHS Determinations to Investigator, Institutional Officials, and Regulatory Agencies .....	111
14.9. Retaliation .....	112
<b>15. Suspension or Termination of Research .....</b>	<b>112</b>
15.1. Notification to Participants.....	113
15.2. Notification of CHS Determinations to Investigator, Institutional Officials, and Regulatory Agencies .....	114
<b>16. CHS Records .....</b>	<b>114</b>
16.1. Active Study Files .....	115
16.2. Study Record Retention Policy .....	116
16.2.1. Investigator’s Study Records .....	116
16.2.2. CHS Study Records.....	117
16.2.3. Other Study Records .....	117
16.2.4. CHS Meeting Packets .....	117
16.3. Minutes of a Convened CHS Meeting.....	117
16.4. Membership Rosters.....	119
16.5. Policies and Procedures .....	119
<b>17. Sponsored Research.....</b>	<b>119</b>
17.1. Organizational Structure.....	119
17.2. Ethical Assurances.....	120
17.3. Additional Requirements for Clinical Trials .....	120
17.4. Requirements for Social/Behavioral Research .....	120
<b>18. Participant Outreach .....</b>	<b>121</b>
18.1. Consent form Requirements .....	121
18.2. CHS Contact Information and Procedures .....	121
18.3. HMS and CHS Websites .....	121